Claims
- 1. A method for preparing stable plurilamellar vesicles, comprising:
- (a) forming a dispersion of at least one amphipathic lipid in an organic solvent;
- (b) combining the dispersion with a sufficient amount of an aqueous phase to form a biphasic mixture in which the aqueous phase can be completely emulsified; and
- (c) concurrently emulsifying the aqueous phase while evaporating the organic solvent of the biphasic mixtures,
- wherein the stable plurilamellar vesicles produced are substantially free of MLVs, SUVs, and REVs.
- 2. The method according to claim 1, wherein the ratio of volume of solvent to volume of aqueous phase is from about 3:1 to about 100:1.
- 3. The method according to claim 1, wherein the temperature at which the method is performed is from about 4.degree. C. to about 60.degree. C.
- 4. The method according to claim 1, wherein the temperature at which the method is performed is less than the phase transition temperature of at least one of said lipids.
- 5. The method according to claim 1, wherein the solvent is fluorocarbon or diethylether, or mixtures thereof.
- 6. The method according to claim 5 wherein the solvent contains an anti-oxidant.
- 7. The method according to claim 6, wherein said anti-oxidant is butylated hydroxytoluene.
- 8. The method according to claim 1 wherein a material to be entrapped in the vesicles is added with the aqueous phase.
- 9. The method according to claim 8, wherein at least 20 percent of said material is entrapped in the vesicles.
- 10. The method according to claim 8, wherein said material is a protein.
- 11. Stable plurilamellar vesicles comprising lipid vesicles ranging from about lOO nm to about 10,000 nm in size, characterized by a few to over 100 lipid bilayers enclosing aqueous compartments containing at least one entrapped solute in which the lipid bilayers have an ordered molecular architecture creating a supramolecular structure which differs from that of other multilamellar vesicles so that when compared to other multilamellar vesicles composed of the identical lipid and aqueous ingredients, stable plurilamellar vesicles have the following properties:
- (a) a higher percent entrapment of solute;
- (b) a lower buoyant density;
- (c) a volume about one-third larger;
- (d) greater stability to auto-oxidation during storage in buffer;
- (e) greater stability in body fluids;
- (f) a larger percent leakage of entrapped solute when exposed to urea, guanidine, or ammonium acetate;
- (g) a smaller percent leakage of entrapped solute when exposed to hydrochloric acid or serum; and
- (h) distribution of entrapped contents throughout the cytosol of cells when administered to the cells in culture.
- 12. Stable plurilamellar vesicles according to claim 11 substantially free of MLVs, SUVs, and REVs.
- 13. The stable plurilumellar vesicles of claim 11 in which the lipid bilayers comprise a phospholipid.
- 14. The stable plurilamellar vesicles of claim 13 in which the phospholipid is amphipathic.
- 15. Stable plurilamellar vesicles according to claim 11, wherein the major lipid component of the vesicles is a phosphatidylcholine.
- 16. Stable plurilamellar vesicles according to claim 11, wherein an anti-oxidant is a component of the vesicle.
- 17. Stable plurilamellar vesicles according to claim 16 wherein said anti-oxidant is butylated hydroxytoluene.
- 18. Stable plurilamellar vesicles according to claim 12, wherein a protein is entrapped within the vesicle.
- 19. Stable plurilamellar vesicles according to claim 12, wherein a compound selected from the group consisting of: antibacterial compounds, antifungal compounds, antiparasitic compounds, and antiviral compounds is entrapped within the vesicle.
- 20. Stable plurilamellar vesicles according to claim 11, wherein a compound selected from the group consisting of: tumoricidal compounds, toxins, cell receptor binding molecules, and immunoglobulins is entrapped within the vesicle.
- 21. Stable plurilamellar vesicles according to claim 11, wherein a compound selected from the group consisting of: anti-inflammatory compounds, anti-glaucoma compounds, mydriatic compounds, and local anesthetics is entrapped within the vesicle.
- 22. Stable plurilamellar vesicles according to claim 11, wherein a compound selected from the group consisting of: enzymes, hormones, neurotransmitters, immunomodulators, nucleotides, and cyclic adenosine monophosphate is entrapped within the vesicle.
- 23. Stable plurilamellar vesicles according to claim 11, wherein a compound selected from the group consisting of: dyes, fluorescent compounds, radioactive compounds, and radio-opaque compounds is entrapped within the vesicle.
- 24. A method for delivery of a compound to cells in vivo, comprising: administering to an organism stable plurilamellar vesicles of claim 11 containing said compound entrapped therein.
- 25. The method according to claim 24, wherein said stable plurilamellar vesicles are administered topically, intraperitoneally, intravenously, intramuscularly, subcutaneously or intraauricularly.
- 26. A method for treatment of infections in animals or plants, comprising: administering stable plurilamellar vesicles of claim 11 containing a compound effective for treating said infection.
- 27. The method according to claim 26, wherein said infection is intracellular.
- 28. The method according to claim 27 wherein said infection is caused by a parasite.
- 29. The method according to claim 28, wherein said infection is caused by Brucella spp.
- 30. The method according to claim 29, wherein said administration is intraperitoneal.
- 31. The method according to claim 26, wherein said infection is extracellular.
- 32. The method according to claim 31 wherein said infection is caused by bacteria.
- 33. The method according to claim 32, wherein said infection is caused by Staphylococcus aureus.
- 34. The method according to claim 33, wherein said administration is intraperitoneal.
- 35. The method according to claim 26, wherein said infection is an ocular infection.
- 36. The method according to claim 35, wherein said infection is caused by a Moraxella spp.
- 37. The method according to claim 36, wherein said administration is topical.
- 38. The method according to claim 26, wherein said infection is caused by a virus.
- 39. The method according to claim 38, wherein said infection is caused by lymphocytic choriomeningitis virus.
- 40. The method according to claim 39, wherein said administration is intraperitoneal.
- 41. A method for treatment of afflictions in animals or plants requiring sustained release of a compound effective for treating said affliction, comprising: administering stable plurilamellar vesicles of claim 11 containing said compound.
- 42. The method according to claim 41, wherein said affliction is an ocular affliction.
- 43. A method according to claim 42, wherein said affliction is glaucoma.
- 44. The method according to claim 43, wherein said administration is topical.
Parent Case Info
The present application is a continuation-in-part of applicant's prior copending applications Ser. No. 463,900 by M. W. Fountain and R. P. Lenk filed Feb. 4, 1983, and now abandoned; Ser. No. 447,247 by R. P. Lenk, M. W. Fountain, A. S. Janoff, filed Dec. 6, 1982, and now abandoned; Ser. No. 411,466 by M. W. Fountain, M. J. Ostro, M. Popescu, and R. P. Lenk, filed Aug. 25, 1982, and now abandoned; Ser. No. 362,995 by M. W. Fountain filed Mar. 29, 1982, and now abandoned; Ser. No. 362,994 by M. W. Fountain filed Mar. 29, 1982, and now abandoned which are herein incorporated by reference.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4115544 |
Shell |
Sep 1978 |
|
4224179 |
Schneider |
Sep 1980 |
|
4235871 |
Papahadjopoulos et al. |
Nov 1980 |
|
Non-Patent Literature Citations (9)
Entry |
Olitzki: "Immunological Methods in Brucellosis Research, Part II: In Vivo Procedures", S. Karger, Basel (Switzerland), 1970, pp. 196-203. |
Gregoriadis: "The Carrier Potential of Liposomes . . . , The New England Journal of Medicine", vol. 295, No. 13, Sep. 23, 1976, pp. 704-710. |
Cecil Textbook of Medicine, 15th Edition, Edited by Beeson et al., W. B. Saunders Co., Philadelphia, 1979, pp. 396-399, 475-479 and 817-821. |
Bangham et al., 1965, J. Mol. Biol. 13:238-252. |
Deamer and Bangham, 1976, Biochim. Biophys. Acta 443:629-634. |
Lenk et al., 1982, Eur. J. Biochem. 121:475-482. |
Papahadjopoulos and Miller, 1967, Biochim. Biophys. Acta 135:624-638. |
Schwendener et al., 1981, Biochem. Biophys. Res. Commun. 100:1055-1062. |
Szoka and Papahadjopoulos, 1978, Proc. Nat'l. Acad. Sci. USA 75:4194-4198. |
Related Publications (4)
|
Number |
Date |
Country |
|
447247 |
Dec 1982 |
|
|
411466 |
Aug 1982 |
|
|
362995 |
Mar 1982 |
|
|
362994 |
Mar 1982 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
463900 |
Feb 1983 |
|